ГЕНЕТИЧЕСКИЕ МАРКЕРЫ КЛИНИЧЕСКИ ВЫРАЖЕННЫХ НЕЖЕЛАТЕЛЬНЫХ ЯВЛЕНИЙ У БОЛЬНЫХ С ВИЧ-ИНФЕКЦИЕЙ, ПОЛУЧАЮЩИХ АНТИРЕТРОВИРУСНУЮ ТЕРАПИЮ

V G Kanestri, К. О. Миронов, Aleksei V. Kravchenko et al. · HIV Infection and Immunosuppressive Disorders · 2014

The presence of the alleles UGT1A1*28 and HLA B*5701 was checked up in 47 and 366 adult HIV patients, respectively. The rate and severity of the adverse effects of using Atazanavir or Abacavir in ART during 2003-2013 were compared with the genetic findings. The prevalences of grade 3 or 4 increases in unconjugated bilirubin and of overt jaundice upon ART were 36,2% and 10.6%, respectively. The highest risk of profound hyperbilirubinemia was featured by patients homozygotic for UGT1A1*28. This allele was found in 57,4% of patients, including 14,9% homozygotes. HLA B*5701 was found in 13 patients (3,7%). Taking account of testing results decreased the rate of ART discontinuation to 4,7%. The specificity of the test was 100% and its sensitivity and informativeness was 99,2%.

Cited by 1 works. doi:10.22328/2077-9828-2014-6-2-49-57

Authors